Impact of New Biomarkers on Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation

Impact of New Biomarkers on the Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation

The Biorhythm study aims to investigate the utility of new biomarkers (e.g. MR proANP, ST2) measured pre-procedure for the prediction of procedural success in patients with atrial fibrillation undergoing cardioversion or ablation.

This is a prospective, observational, multicentre study of patients with paroxystic or persistent atrial fibrillation scheduled to undergo cardioversion or ablation of AF in routine practice. Serum levels of MR proANP and ST2 pre-procedure will be measured to attempt to identify a threshold that carries prognostic value for procedural success (maintenance of sinus rhythm at one year).

Inclusion Criteria:

• Patients with paroxystic or persistent atrial fibrillation for whom a decision to perform ablation is made.
• Patients with persistent atrial fibrillation for whom a decision to perform cardioversion is made.
• Patients with social security coverage, or beneficiary thereof.
• Patients who provide written informed consent.

Exclusion Criteria:

• Age <18 years or >80 years
• Patients with significant valvular heart disease defined as symptomatic aortic valve disease, severe aortic or mitral stenosis or tricuspid or mitral insufficiency grade 3/4 or 4/4
• Patients with pulmonary arterial hypertension >45 mmHg on echocardiography
• Patients with chronic respiratory disease, chronic obstructive pulmonary disease stage II, III or IV.
• Patients with a left ventricular ejection fraction <45%
• Patients with recent (<1 month) acute decompensation of heart failure
• Patients with recent (<1 month) acute coronary syndrome
• Anemia (hemoglobin <10 g/dL)
• Pregnant or lactating women
• Patients with anticipated poor compliance, as assessed by the study investigator
• Patients within the exclusion period of another clinical study
• Patients under legal guardianship